Figure S1 A a b c 10× Ikkβ WT Ikkβ Mye  /  B C n=5, p<0.01 n.s S-100 Mart1 S-100Ikkβ wt Ikkβ Mye  /  Mart1 D Ikkβ wt Ikkβ Mye  /  Ikkβ WT Mock

E Ikkβ WT Ikkβ Mye  /  Ikkβ WT Ikkβ Mye  /  Figure S1 p<0.01, n=5 n.s F GH n=5, p<0.01 n.s Ikkβ WT Ikkβ Mye  /  Ikkβ WT Ikkβ Mye  /  Ikkβ WT Tumor-Free Ikkβ Mye  /  Ikkβ WT Mock

Figure S1 Ikk WT Ikkβ Mye  /  I a b ** n=5 n=2 J K L

Figure S1 14/20 18/20 p<0.01, n=20 M N Ikkβ WT Ikkβ Mye  /  p<0.01, n=20 18/20 8/20 O P Ikkβ WT Ikkβ Mye  /  Day 0 Day 27 Day 7 Day 9 Dox drinking water Tumor progression Collected lungs Injected i.v. with B16 cells Q Ikkβ Mye  /  Ikkβ WT Ikkβ Mye  /  Ikkβ WT

a B A b c a b c Figure S2 M  43% F4/80 CD45 M  9% M  3% F4/80 Gr-1 M  2% M  97% M  13% Neu 50% Neu 0.2% Neu 92% CD45 CD11c DC: 3.9% DC: 2.1% DC: 3.6% d ef CD45 D p<0.05, n=5 n.s. IgG Ly6G Ly6G-PE C

Figure S2 E

Figure S3 A B Gated cells 80% Myeloid Cells 92% F4/80 GFP M  93% GFPNumber FSC SSC IKKβ Mye  /  IKKβ WT C Ikkβ Mye  /  Ikkβ WT Myeloid cellsMelanoma cellsInteraction overlay

A B p<0.01 p<0.05 p<0.01 C n.s Figure S4 IgG CD8 CD8-APC D E 95±2.2, n=6 1.2± ±0.2 Ikkβ WT Ikkβ Mye  / 

Figure S5 A B CD45 CD8 IgG CD8.. CD45 CD8 IgG CD8.. CD45 CD8 IgG CD8. C

ns Ikkβ CA Ikkβ WT D E Figure S5 +Ctrl-Ctrl Ikk  wt Ikk  CA TRP2 tetramer CD8

Figure S6 CD163 Phospho-p65 Fluorescent Intensity Pre-treatment A B C Fluorescent Intensity Post-treatment CD8 CD107a Merge a a a b b bc

Fluorescent Intensity Post-treatment Figure S6 D Fluorescent Intensity Pre-treatment E CD8 + CD107a - CD8 + CD107a + F ba a a b b Fluorescent Intensity CD163 Phospho-p65 CD107a